Category Archives: Chronic Disease

Lyme Disease Treatment with Andrew Heyman, MD, MHSA

Andrew Heyman, MD, MHSA, an internationally recognized expert in Integrative Medicine and the current Director of Integrative Medicine at The George Washington University, spends much of his time as a ‘last resort’ practitioner. Dr. Heyman treats patients who have continuously been seeking treatment–some for months, others for years–but who have received no cure, no explanation, no answers.

Dr. Heyman’s ability to treat these unique patients may stem from his training at the University of Michigan, as a clinical working group co-chair of the Consortium of Academic Health Centers for Integrative Medicine, or from his educational background editing medical journals. Yet his exceptional aptitude in finding answers despite puzzling patient presentations is most likely a result of his background in Traditional Chinese Medicine combined with his conventional medicine training. “Traditional Chinese Medicine taught me how to listen very closely to patients, and to look for patterns of illness expression that sometimes escapes a standard evaluation. My research now seeks to bridge the gap between what we observe in patients and their underlying metabolic and genomic expression, especially in complex presentations.”

Although it is but one of his specialties among a litany of syndromes and diseases, Dr. Heyman has become known as the ‘go-to’ doctor for an often misdiagnosed, misunderstood disease that has recently gained heightened visibility: Lyme disease. Introduced to Lyme through personal and practical experience, Dr. Heyman first became involved in the treatment of the disease after a group of his patients in Virginia presented with a similar pattern of symptoms, and failed to respond to conventional or integrative therapies.

First recognized in the United States in 1975 after a puzzling and unexplainable outbreak of debilitating health issues near Lyme, Connecticut, it was not until 1982 that doctors identified the correlation between deer ticks and Lyme disease. The disease is caused by several strains of the bacteria Borrelia burgdorferi, transmitted to humans through the bite of an infected tick. Once a tick emerges from an egg, it frequently becomes infected during its larval or nymph stage, as it feeds off small animals like squirrels, mice, or birds that carry the Lyme-causing bacteria. During the tick’s subsequent feeding cycle, it passes the bacteria to a human, or another animal.

Early symptoms of the disease often manifest as a flu-like illness, with accompanying fever, chills, muscle aches, and joint pain. While the characteristic ‘bulls-eye’ rash called erythema migrans is often present, many people develop a different type of rash, or none at all. Moreover, a host of Lyme symptoms occur in other diseases, and as a result, many patients suffering from Lyme disease are misdiagnosed with conditions like fibromyalgia, multiple sclerosis, and other psychiatric illnesses, before being correctly treated.

If Lyme is not diagnosed or treated in its early stages, it transitions to a chronic, highly problematic late-stage disease, and symptoms increase in their severity. Untreated Lyme disease will eventually infect joints, the heart, and the nervous system-causing nerve paralysis and meningitis, and difficulty with memory and concentration. While one of the defining features of chronic Lyme disease is fatigue, Dr. Heyman discusses his own cases in which there were a myriad of presentations without any one defining symptom. Many of his patients had suffered severe cognitive decline, loss of executive function, memory problems, mood disturbances, chronic pain, cardiopulmonary problems and more. The debilitating effects of the disease then led to more devastating results: these patients often are unable to work, function in personal relationships, or complete simple daily activities without experiencing profound exhaustion.

There are approximately 329,000 new cases of Lyme disease each year, and the number of those infected is expected to increase. According to Rick Ostfeld, a disease ecologist at the Cary Institute of Ecosystem Studies, the illness is on track to produce its worst numbers in 2017. Moreover, many experts believe the true number of Lyme cases is higher than reported, as the Centers for Disease Control and Prevention require ‘objective measures’ like positive blood tests or rashes; therefore, estimates indicate that CDC surveillance only captures approximately 10% of reportable Lyme cases. There is currently no vaccine for Lyme disease, and Dr. Heyman notes that the FDA-approved blood tests are often inaccurate.

Dr. Heyman’s own research has pinpointed neurological inflammation and even damage that can occur in patients with Lyme. He and his colleagues have utilized specialized brain MRIs originally designed for Alzheimer’s and Parkinson’s, and found significant injury to the brain in many individuals infected with Lyme. “We have gone even further to show how the genetic material of the body actually starts behaving inappropriately in Lyme patients…as we dug and dug, we have realized the degree to which people were sick-and that we have to characterize this illness not just in terms of being an infectious disease, but re-characterize it as being a brain injury disease that has a very strong genomic component.”

Because of the multi-faceted and complex nature of Lyme, neither standard nor functional medical treatments work very well in this patient population, nor is it enough only to treat the infection in many patients. “In my ‘island of misfit toys,'” says Dr. Heyman, “common complaints such as fatigue and weight gain can be wrapped in a much deeper problem such as Lyme that may be underlying the clinical presentation. To successfully treat Lyme patients, one must eradicate the infection, resolve the chronic inflammatory response and repair the injury to the brain – all of which is possible with targeted therapies to restore patients back to health.” A true specialist in this field, therefore, must have an extraordinary ability and capacity to treat the patient as a whole, with experience and skill in not only hormonal balance, stress management, microbiome health, and detoxification, but also genomics, brain trauma and injury, chronic infections, and mold exposure-along with managing other complicated factors associated with Lyme disease.

Please follow and like us:

The Cost of Chronic Disease

The primary issue that consumes the majority of the burden of healthcare costs in the United States is preventable chronic disease: while the most prevalent health conditions are simultaneously the most avoidable, they continue to cost the country’s budget billions of dollars. While overall numbers have decreased since 2010, when chronic disease cost the U.S. a total of $315 billion, morbid obesity rates have continued to rapidly spike—a condition that leads to a range of critical health issues including heart disease, diabetes, and stroke.

Primary care providers have long faced the struggle of determining how to implement best practice care for patients diagnosed with chronic diseases. Recent studies indicate that almost half of the entire U.S. population has at least one chronic health condition—including heart disease, cancer, diabetes, obesity, or arthritis. Statistics designate these health care treatments costs to account for 86% of cumulative national healthcare spending, and the CDC reports that chronic conditions are the leading causes of death and disability in the country.

Yet the past decade has seen the advent and proliferation of digital health technology, spurring the generation of new techniques and strategies for healthcare professionals to utilize in chronic disease management. These types of technology vary in terms of accessibility and usability, but include remote monitoring, mobile health apps installable on phones, and wireless wearables—which serve as activity trackers.

A series of interviews conducted by Medical News Today demonstrate a bright future for the potential of new technology, and its ability to spur and provide high-quality care. Suzanne Falck, MD, an associate professor of internal medicine at the University of Illinois College of Medicine, noted that a highly successful digital tool is currently in use for the management of heart failure: an implanted sensor immediately transmits data to a healthcare practitioner, who then analyzes the data in order to make medical recommendations. Further clinical trials and studies indicate that remote monitoring is more cost-effective than traditional, conventional management.

Moreover, the burgeoning popularity of medical apps signifies that mobile technology can make a hugely positive impact on chronic disease management. There are currently approximately 259,000 medical health apps available to purchase; over half are aimed at targeting consumers with chronic conditions. Clinical trials have repeatedly shown that patients with type 2 diabetes who utilized an app to monitor their blood glucose levels showed greater benefits than those who did not. A recent article in Diabetes Technology & Therapeutics states that the prognosis in patients with diabetes is ‘strongly influenced by the degree of control of their disease,’ which reinforces the effectiveness of self-management support through mobile apps.

Another innovative and exciting development is wearable technology and devices, which are currently being studied in a variety of clinical research settings. Many healthcare providers believe that the ‘potential of this technology is endless,’ as they can improve access to care while simultaneously enhancing convenience—and likely patient compliance.

Most importantly, being conscious of medicinal needs and treatments requires a consistently high level of responsibility and awareness. Healthcare experts urge patients to take active, informed roles in managing their health: online workshops have been developed to offer chronic disease self-management programs, which have been proven to significantly improve health statuses. Moreover, healthcare practitioners and professionals must collectively work together and utilize the new landscape of digital medical technology to their patients’ benefits.

Please follow and like us:

InternalMedReview – Inflammation Induced Chronic Fatiguing Illnesses

This is the state of the science regarding genomics and neuro-inflammation due to Lyme and Mold exposure. The premise is that the common presenting symptom of fatigue is caused by chronic inflammation, which can now be objectively measured and treated when due to a biotoxin exposure. This is breakthrough research and links inflammation, brain injury and underlying genomics. We are the only group in the world to publish these findings based on years of careful research. – Andrew Heyman, MD

We hear so much about genetics vs. genomics here at A4M/MMI, but the bottom line is that a huge leap was just made this month in our main mission. One of our leading faculty members, Andrew Heyman, MD who is also the Program Director of our Fellowship at George Washington University, just had his research published in The Internal Medicine Review’s October Issue.

Dr. Heyman along with another one of our expert faculty members, Dr. Richie Shoemaker, partnered in this research initiative and have worked tirelessly to gather this data. They are the only group in the world that has collected this amount of data in the chronic illness arena. As we continue to review the model of genomics, what is causing chronic disease – between genetics, DNA, RNA, etc. we have begun to become aware of an overlap with other conditions that we usually blame on lifestyle like obesity and diabetes, etc.

Is the presence of mold or moisture in our surroundings starting to shift our immune response?

Below we provide a summary on some exciting new insight into chronic diseases.

Inflammation Induced Chronic Fatiguing Illnesses: A steady march towards understanding mechanisms and identifying new biomarkers and therapies.

Ritchie C. Shoemaker1,4*, Andrew Heyman2, Annalaura Mancia3 and James C Ryan4
1Center for Research on Biotoxin-Associated Illnesses, Pocomoke, MD, USA
2Integrative Medicine, George Washington University, Washington DC, USA
3Department of Life Science and Biotechnology, University of Ferrara, Ferrara, Italy
4ProgeneDX, LLC, Deerfield Beach, FL USA

This breakthrough peer reviewed publication outlines the Chronic Inflammatory Response Syndrome (CIRS), an evidence-based model of assessment and treatment of Chronic Fatigue utilizing objective biomarkers, structural Brain MRI and transcriptomics, and moves medicine away from a ‘symptom only’ approach to managing the fatigued patient. CIRS is a neuroregulatory-inflammatory disease process found in genetically susceptible patients (20% of US population), initiated by exposure to a biotoxin(s) such as a water damaged building, Lyme disease, ciguatera, pfistera and many more. A final common pathway of immune dysfunction ensues, including abnormal findings such as Transforming Growth Factor Beta (TGFb), Vasoactive Intestinal Peptide (VIP), Melanocyte Stimulating Hormone (MSH), split products of complement activation, Matrix Metalloproteinase (MMP9) and others now available for use as clinical diagnostics. In cases of cognitive decline, new technology for brain MRI analysis, NeuroQuant, can pick up small changes in brain structures consistently shown in CIRS.

This work is based upon two randomized controlled trials applying a specific series of assessments and treatments designed to restore normal health status by:

1) eliminating the exposure
2) resolving immune dysfunction
3) repairing damage to the central nervous system

The CIRS protocol finally gives the practitioner a clinical roadmap for some of their most complex patients presenting with fatigue, especially those suffering from Lyme disease. This article offers clear, concise guidance on the diagnostic and therapeutic approach to define both an initial infectious process and a subsequent inflammatory illness and outlines how genomic testing can determine predisposition to chronic stages of Lyme after acute illness through use of Next Generation Sequencing to bring transcriptomics to the Lyme community.

The goal of this important scientific work is to help practitioners reduce uncertainty in their management of the CIRS patient and to ensure a rigorous, evidence based assessment and treatment process is applied utilizing both conventional and Integrative treatment strategies. It represents a new era in clinical medicine by applying a novel language of neuroimmune and genomic profiling, in order to guide health providers in their treatment of Lyme disease, mold exposure and other biotoxins.

Future research will focus on refining the treatment protocol, determining the role of transcriptomics in chronic inflammatory processes and exploring the relationship and overlap between CIRS and other common conditions such as cardiovascular disease, diabetes and obesity, chronic pain syndromes, concussion and brain injury, and neurodegenerative disorders.

On Friday, December 15, 2017 during our 25th Annual A4M World Congress, Dr. Heyman will be lecturing at our VIP breakfast symposium titled See the Forest through the Trees: Protocols for Lyme Disease, where he will cover what can reduce symptoms, of Lyme, strengthen the immune system, and potentially treat the entire illness.

If you are interested in furthering your coverage of the treatment of Lyme and other chronic illnesses, Dr. Heyman and Dr. Shoemaker have a two part online advance course that we offer.

Please follow and like us: